Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 4

1(100.0%)

1Total

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07475832Completed

Comparison of Two Biometers in Dense Cataracts

Role: lead

NCT06064916Completed

Visual Outcomes and Patient Satisfaction With Vivity IOL in Post Refractive Patients

Role: lead

NCT06041139Completed

Visual Outcomes and Patient Satisfaction With Bilateral PanOptix Verses Bilateral Synergy

Role: lead

NCT05611073Completed

Maximizing Visual Outcomes With Eyhance IOLs

Role: lead

NCT06045325Completed

Assessment of Measurement Variability Across Automated Biometry Devices

Role: lead

NCT06922084Phase 4Recruiting

A Prospective, Randomized, Subject and Vision-assessor Masked, Multicenter Study Comparing Bilateral Clareon PanOptix, Bilateral Clareon PanOptix Pro, and Mixed Clareon PanOptix Pro/Vivity Intraocular Lens Implantation in Cataract Subjects

Role: lead

NCT05226884Completed

Intermediate Vision in Patients With Clareon IOLs Compared to Eyhance IOLs

Role: lead

All 7 trials loaded